WO1995023605A1 - Procede de traitement et d'inhibition des ulceres gastriques et duodenaux - Google Patents

Procede de traitement et d'inhibition des ulceres gastriques et duodenaux Download PDF

Info

Publication number
WO1995023605A1
WO1995023605A1 PCT/US1995/002388 US9502388W WO9523605A1 WO 1995023605 A1 WO1995023605 A1 WO 1995023605A1 US 9502388 W US9502388 W US 9502388W WO 9523605 A1 WO9523605 A1 WO 9523605A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligosaccharide
galactose
group
stomach
formula
Prior art date
Application number
PCT/US1995/002388
Other languages
English (en)
Inventor
David A. Zopf
Paul M. Simon
Stephen Roth
Edward J. Mcguire
Dennis H. Langer
Original Assignee
Neose Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Pharmaceuticals, Inc. filed Critical Neose Pharmaceuticals, Inc.
Priority to JP52295595A priority Critical patent/JP3179108B2/ja
Priority to EP95911945A priority patent/EP0749314A4/fr
Priority to AU19323/95A priority patent/AU709149B2/en
Publication of WO1995023605A1 publication Critical patent/WO1995023605A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates a method for treating and inhibiting gastric and duodenal ulcers in a patient.
  • H. pylori Helicobacter pylori
  • Campylobacter pylori C. pylori
  • H. pylori has been isolated in gastric tissue biopsies in patients throughout the world. While the precise mechanism of inflammation is not well understood, H. pylori is found in association with the apical surfaces of gastric mucous- secreting cells.
  • H. pylori Due to the site specificity of attachment, it has been suggested that there are specific attachment sites for H. pylori which exist on gastric and duodenal mucous-secreting cells. Numerous studies have been undertaken to attempt to identify the specific binding site of H . pylori . Evans et al (Infection and Immunity (1988) 56:2896- 2906) reported that H.
  • N-acetylneuraminyl- (2 ⁇ 3)-Gal /3l ⁇ 4 Glc herein after NeuAc(2 ⁇ 3)-lactose
  • N-acetylneuraminyl- ⁇ (2 ⁇ 6)-Gal ⁇ l ⁇ 4 Glc herein after NeuAc(2 ⁇ 6)-lactose
  • Sialoproteins which contain the NeuAc(2 ⁇ 3)Gal isomer of NeuAc-lactose i.e., human erythrocyte glycophorin A, fetuin, and human ⁇ 2 - macroglobulin, also inhibited H. pylori binding, but at higher concentrations (mg/ml) than that observed for NeuAc(2 ⁇ 3)-lactose, while no inhibition was observed for the corresponding asialoglycoproteins.
  • Evans et al ibid measured the hemagglutination inhibiting ability (HIA) of several compounds containing a NeuAc-lactose structure.
  • the researches determined that in order to produce 100% HAI, 1.000 mg/ml of ⁇ 2 -Macroglobulin was needed, 0.500 mg/ml of fetuin was needed, 0.250 mg/ml of Glycophorin A was needed and 0.078 mg/ml of bovine NeuAc-lactose was needed.
  • Lin wood et al (Lancet (1989) 2 :238-241) have reported the isolation of a gastric glycerolipid material which they observed to behave as a receptor for H. pylori .
  • the material was isolated from red blood cells, and mucosal scrapings of pig stomach and human stomach. The investigators postulated that the material was a sulphated alkylacylglycero-lipid, but the actual structure of this material was not been reported. Subsequent investigations (Lincfwood et al.. Infection and Immunity (1992) 60:2470- 2474) showed that this receptor is phosphatidylethanolamine. Lin wood et al..
  • H . pylori adherence can be assessed by microtiter assays and involves a bacterial surface material which co-purifies with urease and is different from the N- acetyl-neuraminyl-lactose binding hemagglutinin.
  • Saitoh et al report a sulfate-containing glycerolipid as a ligand which is specifically recognized by H. pylori .
  • CBS Colloidal bismuth subcitrate
  • CBS has been used successfully in treating both gastric and duodenal ulcer diseases (for a review, see Lambert in Reviews of Infectious Diseases (1991) 13. (Suppl. 8) :S691-5.
  • CBS has proven effective as a histamine H 2 antagonist and has been associated with lower relapse rates after cessation of therapy attributed to CBS's ability to eradicate H. pylori .
  • Bismuth subsalicylate (BSS) has also been observed to inhibit H. pylori .
  • H. pylori plays in peptic ulcers has led to an announcement in February 1994 by an independent advisory panel of experts convened by the National Institutes of Health, to advise that patients diagnosed with peptic ulcers and H. pylori be treated for two weeks with a combination of antibiotics.
  • fetuin has minimal activity in inhibiting binding of H. pylori cells, in vitro .
  • the inventors have discovered that the binding inhibition activity associated with fetuin, appears to be attributable to a high molecular weight impurity which is a contaminate of commercially available fetuin.
  • 3' sialyl lactose has an ability to inhibit binding of H. pylori to a degree far in excess of what would have been expected in light of that previously reported for fetuin.
  • one object of the present invention is to a method for treating and/or preventing gastric and/or duodenal ulcers.
  • Another object of the present invention is to provide a method for inhibiting Helicobacter pylori infection and/or reinfection to mammalian tissue, including eliminating Helicobacter pylori from the stomach and/or duodenum of a patient in need thereof.
  • Another object of the present invention is to provide a pharmaceutical composition for inhibiting Helicobacter pylori infection or reinfection of mammalian tissue, including eliminating Helicobacter pylori from the stomach and/or duodenum of a patient in need thereof and for treating and/or preventing gastric and/or duodenal ulcers.
  • All of the above objects of the present invention and other objects which are apparent from the description of the invention given herein below have been discovered by the inventors to be satisfied by administering a composition comprising an oligosaccharide of Formula I (NeuAc- ⁇ (2-3)-pGal-/3(1)-(-X-) m -(-Y-) n -) p -Z wherein
  • X a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z; wherein the C x glycosidic oxygen of galactose may be replaced by N, S or C;
  • Y a linking group
  • Z a multivalent support
  • m 0 or 1
  • n 0 or 1
  • p an integer of 2-1,000.
  • the present invention is also provided for by an oligosaccharide composition of Formula II
  • oligosaccharide of Formula I i.e. the oligosaccharide of Formula I
  • oligosaccharide of Formula I a multivalent presentation of an oligosaccharide is unexpectedly superior, on a molar basis based on the oligosaccharide groups, than the monovalent presentation of the same oligosaccharide.
  • a method in which a pharmaceutical composition comprising the oligosaccharide of Formula I and/or Formula II alone, or in combination with an H 2 blocker, an antibiotic, oligosaccharide compounds and/or an antiulcerative compound is administered to a mammal has been found by the inventors to be effective at inhibiting the binding of Helicobacter pylori to the gastric and duodenal mucosa and relieving the effects of gastric and duodenal ulcers.
  • X a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z; wherein the C x glycosidic oxygen of galactose may be replaced by N, S or C;
  • X can be a substituted C . 20 alkyl group, a substituted C-.. 20 alkyl carboxylic ester group, a substituted C. ⁇ 20 alkyl carboxy amide group, a hydroxy terminated polyether, an amine terminated polyether, inositol, an oligosaccharide, a disaccharide or a monosaccharide with the terminal reducing end of the oligosaccharide, disaccharide or monosaccharide in the pyranose or open chain form, an azaoligosaccharide, an azadisaccharide or an azamonosaccharide with the terminal reducing end of the azaoligosaccharide, azadisaccharide or azamonosaccharide in the pyranose or open chain form, wherein said substitution is capable of reacting with the linking group of the multivalent support, such as a hydroxyl group or an amine group.
  • the group X is a monosaccharide hexose group such as glucose, N-acetylglucosamine, galactose, N- acetylgalactosamine, mannose, fucose, allose, altrose, gulose, idose, talose and rhamnose.
  • a suitable group X is a reduced form of the above-identified hexose groups, such as glucitol.
  • n 0.
  • a suitable linker group has one terminal portion of the Y group capable of bonding with the group X, while the other terminal end is capable of bonding with the multivalent support.
  • a bond between X and Y can be formed by reacting an aldehyde or carboxylic acid at C-. of the X group or any aldehyde or carboxylic acid group introduced onto the X group by oxidation, with the Y group, to form a suitable bond such as -NH-, -N(R)- where R is C- . . 2 - alkyl, a hydroxyalkylamine, a amide, an ester, a thioester, a thioamide.
  • X is a saccharide such as an oligosaccharide, a disaccharide or a monosaccharide
  • a bond between X and Y can be formed by reacting the C hydroxyl group, in the pyranose form with an acylating agent and a molecular halide, followed by reaction with a nucleophile to form a suitable bond such as -NH-, -N(R)- where R is C- . . 2 - alkyl, - S- and -0-.
  • This type of linking chemistry is described by Stowe11 et al Advances in Carbohydrate Chemistry and Biochemistry, 31_ (1980) p 225+.
  • a suitable multivalent support is a compound with multiple binding sites to a terminal end of the linking group, which is not bound to the group X of the linking group, with multiple binding sites to the group X, or with multiple binding sites to the C x glycosidic oxygen of galactose.
  • Examples include but are not limited to a polyol, a polysaccharide, polylysine, avidin, a polyacrylamide, dextran, lipids, lipid emulsions, liposomes, a dendritomer, human serum albumin, bovine serum albumin or a cyclodextrin.
  • the oligosaccharide is provided as a multivalent molecule according to Formula I.
  • the oligosaccharide portion is bound to a multivalent support using known techniques so as to produce a conjugate in which more than one individual molecule of the oligosaccharide is covalently attached through a linker to the multivalent support.
  • the oligosaccharide portion can be bound to the multivalent support via the free anomeric carbon of the group X.
  • the oligosaccharide portion can be bound via a phenethylamine-isothiocyanate derivative as described by Smith et al. Complex Carbohydrates part C, Methods in Enzymology, volume L, Ed by V. Ginsburg (1978) , p 169-171. It is preferable that the oligosaccharide of Formula I remains soluble in water, however it is also possible to administer the oligosaccharide of Formula I in the form of polymer particles.
  • the oligosaccharide portion of Formula I may be bound to a support to form a bead wherein the surface of the bead is bound with the oligosaccharide portion of Formula I.
  • A a group capable of bonding to the p galactose; wherein the C- L glycosidic oxygen of galactose may be replaced by N, S or C; is administered according to the present method.
  • A can be a C 1 _ 20 alkyl group, a C ⁇ Q alkyl carboxylic ester group, a C x _ 20 alkyl carboxy amide group, a polyether, inositol, an oligosaccharide, a disaccharide or a monosaccharide with the terminal reducing end of the oligosaccharide, disaccharide or monosaccharide in the pyranose or open chain form, an azaoligosaccharide, an azadisaccharide or an azamonosaccharide with the terminal reducing end of the azaoligosaccharide, azadisaccharide or azamonosaccharide in the pyranose or open chain form,
  • the group A is a
  • a suitable group A is a reduced form of the above-identified hexose groups, such as glucitol.
  • the corresponding N and S glycosides of galactose can be prepared by conventional methods known to those of ordinary skill in the art from galactose followed by attachment of a sialyl acid group at the 3 position by conventional methods.
  • the corresponding C glycoside of galactose can be made by conventional synthetic organic techniques, followed by attachment of a sialyl acid group at the 3 position by conventional methods.
  • Suitable pharmaceutically acceptable cations may be used with the oligosaccharides of Formula I and Formula II, to form a salt of the carboxylic acid group.
  • Suitable cations include conventional non-toxic salts including a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) or an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethyla ine salt, triethyla ine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N, N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g.
  • a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) or an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethyla ine salt,
  • formate acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.
  • an inorganic acid salt e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • a salt with an amino acid e.g. arginine salt, aspartic acid salt, glutamic acid salt, etc.
  • the oligosaccharides of the present invention may be obtained using any known method, including (1) enzymatically, using one of the inventor's method described in published international application WO 91/16449, (2) synthetically, using classical organic chemistry, (3) by degradation of a natural occurring oligosaccharide, glycolipid, or glycopeptide or (4) isolation from natural source such as bovine colostrum.
  • the isolation of 3' sialyl lactose from bovine colostrum is described in Veh et al, Journal of Chromatography, 212, (1981) 313-322.
  • the oligosaccharides of Formula I and Formula II may be administered in conjunction with a known proton pump inhibitor or a known H 2 receptor antagonist.
  • a representative proton pump inhibitor is omeprazole
  • representative H 2 antagonists include cimetidine, ranitidine, nizatidine and famotidine.
  • the amount of proton pump inhibitor and H 2 antagonist administered in conjunction with the present oligosaccharide is about the same amount administered for their known therapy. Accordingly, effective dosages of the proton pump inhibitor and H 2 can be determined by routine experimentation.
  • Suitable antiulceratives include aceglutamide aluminum complex, e-acetamidocaproic acid zinc salt, acetoxolone, arbaprostil, benexate hydrochloride, bismuth subcitrate sol, bismuth subsalicylate, carbenoxolone, cetraxate, cimetidine, enprostil, esaprazole, famotidine, ftaxidide, gefarnate, guaiazulene, irsogladine, misoprostol, monatidine, ornoprostil, ⁇ - oryzanol, pifamine, pirenzepine, plaunotol, ranitidine, rioprostil, rosaprostol, rotraxate, roxatidine acetate, sofalcone, spizofurone, sucralfate
  • the amount of antiulcerative administered in conjunction with the present oligosaccharide is about the same amount administered for its known therapy. Accordingly, effective dosage of the antiulcerative can be determined by routine experimentation.
  • the oligosaccharides of Formula I and Formula II may be administered in conjunction with an antibiotic with activity against H. pylori . Suitable antibiotics include metronidazole, tetracycline, bismuth, erythromycin, a macrolide, a quinolone, a cephalosporin and amoxicillin.
  • the amount of antibiotic administered in conjunction with the present oligosaccharide is about the same amount administered for its known therapy. Accordingly, effective dosage of the antibiotic can be determined by routine experimentation.
  • Formula II may be administered in conjunction with a H-type 1 or Lewis b blood group antigen or an oligosaccharide such as NeuAc- ⁇ (2 ⁇ 6)-Gal / 3l ⁇ 4 Glc.
  • a H-type 1 or Lewis b blood group antigen or an oligosaccharide such as NeuAc- ⁇ (2 ⁇ 6)-Gal / 3l ⁇ 4 Glc.
  • Suitable H-type 1 and Lewis b blood group antigens are reported in Boren et al (Science (1993) 262:1892-1895) .
  • the anti-H. pylori compositions of the present invention contains the oligosaccharides of Formula I and Formula II in association with any suitable liquid or solid, pharmaceutically acceptable carrier or excipient, preferable in a form suitable for oral or enteral administration.
  • the pharmaceutical compositions of the present invention are preferably pyrogen free.
  • compositions are usually administered as a mixture with a carrier suitably selected depending upon the route for administration using standard formulations.
  • the compound of the present invention may be administered in the form of tablets which may be prepared using known techniques by adding to a powder of the active ingredient of the present invention an excipient such as starch, lactose, sucrose, glucose, crystalline cellulose, calcium carbonate or kaolin, a hydroxypropylcellulose, a glucose solution, a sucrose solution, water or ethanol, a disintegrator such as starch, agar, gelatin powder, carboxymethylcellulose calcium (CMC- Ca) , carboxymethylcellulose sodium (CMC-Na) , crystalline cellulose, calcium carbonate or sodium hydrogencarbonate, or a lubricant such as magnesium stearate, calcium stearate, talc, macrogoal 4,000, macrogoal 6,000 or stearic acid.
  • an excipient such as starch, lactose, sucrose, glucose, crystalline cellulose, calcium carbonate or
  • the mixture is then subjected to compression molding by a conventional tableting method, and if necessary, applying a sugar coating by means of a concentrated sugar solution containing e.g. gum arabic, talc, polyvinylpyrrolidone, polyethyleneglycol and/or titanium oxide, applying a film coating by means of a film-forming agent composed of e.g. polyvinyl acetal diethylaminoacetate, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose or polyvinylpyrrolidone or applying an enteric coating by means of a film-forming agent composed of e.g. ethylcellulose phthalate, cellulose acetate phthalate or hydroxypropylmethylcellulose phthalate.
  • a sugar coating by means of a concentrated sugar solution containing e.g. gum arabic, talc, polyvinylpyrrolidone, polyethyleneglycol and/or titanium oxide
  • a film coating by means of a film-
  • compositions may be in the form of granules or fine granules which may be prepared by adding to the active ingredient of the present invention a binder such as starch, gelatin, gum arabic, methylcellulose, sodium carboxymethylcellulose, heavy silicic anhydride or light silicic anhydride, followed by kneading and granulation by usual methods; or as a powder of the active ingredient of the present invention by itself; or as capsules which may be prepared by adding to the active ingredient of the present invention an excipient such as lactose, starch or crystalline cellulose and/or a lubricant such as magnesium stearate, calcium stearate or talc, and filling the mixture into capsules.
  • a binder such as starch, gelatin, gum arabic, methylcellulose, sodium carboxymethylcellulose, heavy silicic anhydride or light silicic anhydride, followed by kneading and granulation by usual methods
  • a solution or suspension may be prepared by adding any diluent customarily, used in the art.
  • suitable diluents include water, ethyl alcohol, propylene glycol, polyoxyethylene sorbitol, and sorbitan esters.
  • Sodium chloride, glucose or glycerol may be incorporated into such a liquid preparation in an amount sufficient to prepare an isotonic solution.
  • the therapeutic composition may also further contain ordinary dissolving aids, buffers, pain-alleviating agents, art preservatives, and optionally coloring agents, fragrances, flavors, sweeteners and other pharmacologically active agents such are well known in the art.
  • Suitable compositions may take the form of a solution, suspension, tablet, coated tablet or any pharmaceutically acceptable form suitable for delivery to the stomach or duodenum.
  • the oligosaccharide or pharmaceutical compositions are administered orally or enterally to a patient in need thereof to inhibit H. pylori binding or eliminate H. pylori colonies from the patient's stomach and/or duodenum.
  • suitable patients are humans.
  • the present method is also applicable to treatment of animals, including but not limited to mammals such as pigs, cows, horses, sheep, goats, dogs, cats, rodents and non-human primates.
  • the method of the present invention is suitable for preventing and treating patients with duodenal ulcers, gastric ulcers and the prevention of gastric cancers in patients.
  • Suitable amounts of the pharmaceutical composition containing the oligosaccharides of Formula I and/or Formula II to be administered include those which produce an effective stomach concentration of oligosaccharide of from 1 ⁇ g to 10,000 mg/ml per dose, preferably 10 ⁇ g to 1,000 mg/ml, more preferably 0.5mg to 50 mg/ml, most preferably 1 to 10 mg/ml.
  • an effective stomach concentration of oligosaccharide of from 1 ⁇ g to 10,000 mg/ml per dose, preferably 10 ⁇ g to 1,000 mg/ml, more preferably 0.5mg to 50 mg/ml, most preferably 1 to 10 mg/ml.
  • a dose of 3 gm would produce an effective stomach concentration of about 6 mg/ml.
  • Administration of the pharmaceutical composition comprising the oligosaccharide of Formula II is performed preferably to achieve a continuous effective stomach concentration of from 1 ⁇ g to 10,000 mg/ml per dose, preferably 10 ⁇ g to 1,000 mg/ml, more preferably 0.5mg to 50 mg/ml, most preferably 1 to 10 mg/ml. This can be achieved by administration, at least daily, preferably twice daily, more preferably three times a day and most preferably four times a day.
  • a pharmaceutical composition comprising the oligosaccharide of Formula I is administered so as to achieve a continuous effective stomach concentration of from 1 ⁇ g to 1,000 mg/ml per dose, preferably 10 ⁇ g to 100 mg/ml, more preferably 50 ⁇ g to 5 mg/ml, most preferably 10 ⁇ g to 2 mg/ml.
  • This can be achieved by administration, at least daily, preferably twice daily, more preferably three times a day and most preferably four times a day.
  • the composition is formulated to provide between 10-500 mg, preferably 100-300 mg of the proton pump inhibitor, H 2 antagonist, or antiulcerative daily.
  • suitable therapies include administration of tetracycline (500 mg four times daily) , bismuth subsalicylate (two tablets four times daily, with meals and at bedtime) , and metronidazole (250 mg three times daily, with meals) each taken for a 14 day period.
  • Dosage forms include such unit dosage forms such as tablets, capsules, solutions or suspensions.
  • maintenance dosages of are administered so as to achieve a continuous effective stomach concentration of from 1 ⁇ g to 1,000 mg/ml per dose, preferably 10 ⁇ g to 100 mg/ml, more preferably 50 ⁇ g to 5 mg/ml, most preferably 10 ⁇ g to 2 mg/ml.
  • This can be achieved by administration, at least daily, preferably twice daily, more preferably three times a day and most preferably four times a day.
  • H. pylori bacteria isolates were obtained from B. Marshall (from the University of Virginia) and grown on sheep blood agar, collected at 48 h, washed and suspended in a binding buffer of HBSS + 0.1% bovine serum albumin + 50mM HEPES buffer + 0.01% phenol red or HBHPR.
  • H. pylori concentration of H. pylori which bound to the monolayer was assigned an intermediate OD 595 (optical density at 595 nm) (about 0.4 OD units).
  • concentration of bacteria and test compound were combined for 10 minutes, then transferred onto the monolayer. Binding was allowed to occur for 20 min at room temperature under mild agitation. The unbound bacteria was washed away with 1 wash of HBHPR, then 2 washes of the same buffer without HEPES buffer (HBPR) .
  • the amount of bacterial adhesion to the monolayer was measured by incubating with 50 ⁇ l urea-phenol red (UPR) solution (0.2% urea, 0.03% phenol red in 0.85% NaCl) .
  • URR urea-phenol red
  • the presence of bound bacteria is indicated by the presence of bacterial urease which generates NH 3 , which raises the pH and changes the color to purple, near at OD 595 .
  • HSA — > 1 x 10 "4 1 3'sialyl lactose-HSA is a complex of 3'sialyl lactose with HSA, with about 20 molecules of 3'sialyl lactose bound to the HSA.
  • the binding inhibiting activity of fetuin was determined as follows:
  • Gnotobiotic derived piglets (delivered by cesarean section and housed in a germ-free environment) were orally treated with 100 mg of 3'sialyl lactose in 5.0 ml of water.
  • gnotobiotic piglets Twenty one day old gnotobiotic piglets were orally treated with seven doses of 100 mg each of 3' sialyl lactose, at about 8 hour intervals. As a control, the piglets were administered water. The third administration of 3' sialyl lactose and control was accompanied with 4 x 10 9 live H. pylori . Four piglets were administered 3'sialyl lactose and 2 piglets were administered the control. The results are shown below in Table 3.
  • the piglets were evaluated by determining bacterial colonies in blood-agar as colony forming units/gram of gastric epithelium (CFU/g) .
  • CFU/g gastric epithelium
  • An anti-Helico-bacter composition is prepared by suspending 1 g of the 3'sialyl lactose in a mixture of water and propylene glycol.
  • Example 4 An anti-Helico-bacter composition is prepared by suspending 1 g of the 3'sialyl lactose in a mixture of water and propylene glycol.
  • An ant i-Helicobacter composition is prepared by mixing 1 g of 3' sialyl lactose with 250 mg of the H 2 receptor antagonist ranitidine. The mixture is then suspended in a mixture of water and propylene glycol. Example 5.
  • An anti-He2icoJbacter composition is prepared by mixing 1 g of 3' sialyl lactose with 250 mg of the proton pump inhibitor omeprazole. The mixture is then suspended in a mixture of water and propylene glycol. Example 6.
  • An anti-Helico-bacter composition is prepared by mixing 1 g of 3' sialyl lactose with 500 mg of a tetracycline. The mixture is then suspended in a mixture of water and propylene glycol.
  • a patient infected with H. pyl ⁇ ri is treated with the composition of Example 3.
  • the patient is treated orally four times daily with each dosage providing an effective stomach concentration of 2 mg/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé traitant et/ou inhibant les ulcères gastriques ou duodénaux par administration d'une composition pharmaceutique comprenant un oligosaccharide de la formule (I): NeuAc-α(2-3)-pGal-β(1)-(-X-)m-(-Y-)n-)p-Z. Dans cette formule générale (I), X représente une liaison chimique ou un groupe pouvant lier le p galactose soit au groupe de liaison Y, soit au support multivalent Z; où l'oxygène glycosidique C1 du galactose est remplaçable par N, S ou C; Y représente un groupe de liaison; Z représente un support multivalent; m est un entier valant 0 ou 1; n est un entier valant 0 ou 1; et p est un entier valant de 2 à 1000. L'invention concerne en outre un procédé traitant et/ou inhibant les ulcères gastriques et duodénaux par administration d'une composition pharmaceutique comprenant un oligosaccharide, de la formule (II): NeuAc-α(2-3)-pGal-β(1)-A. Dans cette formule (II), A représente un groupe pouvant se lier au p galactose; l'oxygène glycosidique C1 du galactose étant remplaçable par N, S ou C.
PCT/US1995/002388 1994-03-02 1995-03-02 Procede de traitement et d'inhibition des ulceres gastriques et duodenaux WO1995023605A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52295595A JP3179108B2 (ja) 1994-03-02 1995-03-02 胃潰瘍及び十二指腸潰瘍を治療及び阻止する方法
EP95911945A EP0749314A4 (fr) 1994-03-02 1995-03-02 Procede de traitement et d'inhibition des ulceres gastriques et duodenaux
AU19323/95A AU709149B2 (en) 1994-03-02 1995-03-02 Method for treating and inhibiting gastric and duodenal ulcers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20451594A 1994-03-02 1994-03-02
US204,515 1994-03-02

Publications (1)

Publication Number Publication Date
WO1995023605A1 true WO1995023605A1 (fr) 1995-09-08

Family

ID=22758224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/002388 WO1995023605A1 (fr) 1994-03-02 1995-03-02 Procede de traitement et d'inhibition des ulceres gastriques et duodenaux

Country Status (5)

Country Link
EP (1) EP0749314A4 (fr)
JP (1) JP3179108B2 (fr)
AU (1) AU709149B2 (fr)
CA (1) CA2183329A1 (fr)
WO (1) WO1995023605A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040169A1 (fr) * 1995-06-07 1996-12-19 Neose Technologies, Inc. Inhibition bacterienne par un compose d'oligosaccharide
WO1997041875A1 (fr) * 1996-05-03 1997-11-13 Neose Technologies, Inc. Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance
WO2000056343A1 (fr) * 1999-03-19 2000-09-28 Boren Thomas Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
EP1165097A2 (fr) * 1999-02-01 2002-01-02 Dermal Research Laboratories, Inc. Composition pharmaceutique d'hydrates de carbone complexes et d'huiles essentielles et methode d'utilisation de celle-ci
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
NL2007931C2 (en) * 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
JP7168770B2 (ja) * 2018-09-20 2022-11-09 エンビアル インコーポレイテッド ヘリコバクター・ピロリ認知用高分子複合体及びそれを含む光線力学治療用組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923980A (en) * 1987-11-10 1990-05-08 Biocarb Ab Process for the manufacture of a gel product
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5254676A (en) * 1991-11-22 1993-10-19 E. I. Du Pont De Nemours And Company Oligosaccharide inhibitors for influenza virus
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0436294A (ja) * 1990-06-01 1992-02-06 Snow Brand Milk Prod Co Ltd 牛乳由来の新規なガングリオシド及びその製造法
AU3881493A (en) * 1992-03-19 1993-10-21 University Of British Columbia, The Method and composition for suppression of side effects of anti-inflammatory drugs
AU4055993A (en) * 1992-05-15 1993-12-13 University Of British Columbia, The N-acetyl glucosamine as gastroprotective agent
WO1994003184A1 (fr) * 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923980A (en) * 1987-11-10 1990-05-08 Biocarb Ab Process for the manufacture of a gel product
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5254676A (en) * 1991-11-22 1993-10-19 E. I. Du Pont De Nemours And Company Oligosaccharide inhibitors for influenza virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0749314A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040169A1 (fr) * 1995-06-07 1996-12-19 Neose Technologies, Inc. Inhibition bacterienne par un compose d'oligosaccharide
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US6001819A (en) * 1995-06-07 1999-12-14 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
WO1997041875A1 (fr) * 1996-05-03 1997-11-13 Neose Technologies, Inc. Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance
AU710576B2 (en) * 1996-05-03 1999-09-23 Neose Technologies, Inc. Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
EP1165097A2 (fr) * 1999-02-01 2002-01-02 Dermal Research Laboratories, Inc. Composition pharmaceutique d'hydrates de carbone complexes et d'huiles essentielles et methode d'utilisation de celle-ci
US8003782B1 (en) 1999-02-01 2011-08-23 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US9220290B2 (en) 1999-02-01 2015-12-29 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
WO2000056343A1 (fr) * 1999-03-19 2000-09-28 Boren Thomas Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates

Also Published As

Publication number Publication date
JPH09509931A (ja) 1997-10-07
JP3179108B2 (ja) 2001-06-25
CA2183329A1 (fr) 1995-09-08
AU709149B2 (en) 1999-08-19
AU1932395A (en) 1995-09-18
EP0749314A4 (fr) 2002-09-18
EP0749314A1 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
US5514660A (en) Method for treating and inhibiting gastric and duodenal ulcers
US4666897A (en) Inhibition of mammalian collagenolytic enzymes by tetracyclines
KR19990022658A (ko) 올리고사카라이드 화합물에 의한 박테리아 저해물질
WO1994003184A1 (fr) Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux
AU709149B2 (en) Method for treating and inhibiting gastric and duodenal ulcers
SK10042003A3 (sk) Použitie látky obsahujúcej Helicobacter pylori
JP2006511497A (ja) ヘリコバクターピロリに対する高親和性レセプターおよびその用途
AU710576B2 (en) Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
US5962423A (en) Treatment of bacterial dysentery
EP1663258A2 (fr) Traitement au moyen d'oligo-beta-(1,3)- glucanes et medicament utilises dans le cadre de ce traitement
PT655249E (pt) Moenomicina como medicamento para o tratamento de ulceras gastricas
WO1998026662A1 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
US20050220819A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
WO1998026662A9 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
JPH07502011A (ja) 免疫抑制性および寛容原性のオリゴ糖誘導体
MXPA98009158A (en) Salt of bismuto de sialiloligosacarido and a metodopara treat and inhibit gastric and duodenal ulceras with the mi
US20060183710A1 (en) Chlamydia oligosaccharides
PT1357917E (pt) Utilização de hidratos de carbono para eliminar infecções intestinais em animais
JP2003535965A5 (fr)
WO2000056343A1 (fr) Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
WO2004065400A1 (fr) Nouveaux epitopes de liaison a helicobacter pylori et utilisation desdits epitopes
HUT60435A (en) Process for producing pharmaceutical composition comprising episialo complex carbonhydrate
Simon Section Review: Biologicals & Immunologicals: Complex carbohydrates in development as human pharmaceuticals
MXPA98001875A (en) Salts of bismuto of antibiotics of the lamoenomycin group, procedure for its preparation, its use and medicines containing such sa
JP2004002239A (ja) ＴＮＦ−α産生抑制剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2183329

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995911945

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995911945

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995911945

Country of ref document: EP